- Home
- ANTX vs BOLD Comparison
ANTX vs BOLD Comparison
Compare ANTX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- BOLD
- Stock Information
- Founded
- ANTX 2017
- BOLD 2018
- Country
- ANTX United States
- BOLD United States
- Employees
- ANTX N/A
- BOLD N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- ANTX Health Care
- BOLD
- Exchange
- ANTX Nasdaq
- BOLD Nasdaq
- Market Cap
- ANTX 33.2M
- BOLD 30.3M
- IPO Year
- ANTX 2022
- BOLD 2024
- Fundamental
- Price
- ANTX $1.07
- BOLD $1.18
- Analyst Decision
- ANTX Buy
- BOLD Buy
- Analyst Count
- ANTX 2
- BOLD 3
- Target Price
- ANTX $2.00
- BOLD $4.00
- AVG Volume (30 Days)
- ANTX 289.9K
- BOLD 353.5K
- Earning Date
- ANTX 08-12-2025
- BOLD 08-11-2025
- Dividend Yield
- ANTX N/A
- BOLD N/A
- EPS Growth
- ANTX N/A
- BOLD N/A
- EPS
- ANTX N/A
- BOLD N/A
- Revenue
- ANTX N/A
- BOLD N/A
- Revenue This Year
- ANTX N/A
- BOLD N/A
- Revenue Next Year
- ANTX N/A
- BOLD N/A
- P/E Ratio
- ANTX N/A
- BOLD N/A
- Revenue Growth
- ANTX N/A
- BOLD N/A
- 52 Week Low
- ANTX $0.87
- BOLD $1.00
- 52 Week High
- ANTX $3.07
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- ANTX 45.19
- BOLD N/A
- Support Level
- ANTX $1.07
- BOLD N/A
- Resistance Level
- ANTX $1.11
- BOLD N/A
- Average True Range (ATR)
- ANTX 0.04
- BOLD 0.00
- MACD
- ANTX 0.00
- BOLD 0.00
- Stochastic Oscillator
- ANTX 28.57
- BOLD 0.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.